Trial Profile
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients ≥65 Years of Age Not Eligible for Intensive Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Azacitidine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DELTA
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
- 01 Jun 2023 Status changed from completed to discontinued.
- 01 Mar 2021 Status changed from recruiting to completed.